Stay updated on MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.

Latest updates to the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedNo significant changes detected on the Study Details page; the study overview, design, eligibility criteria, outcomes, and locations remain unchanged.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedThe page has updated time/status information and removed older status labels; latest dates and counts are now reflected.SummaryDifference0.3%

- Check37 days agoChange DetectedMajor update: added government-operating status notice and links; version bumped from v3.1.0 to v3.2.0 indicating a new release.SummaryDifference1.0%

- Check44 days agoChange DetectedContent expansion and revision: adding new topics (Economics, Health Care Economics and Organizations, Taxes) and updating the version to v3.1.0, while removing older topics (Albumins, Proteins, Albumin-Bound Paclitaxel) and the older version v3.0.2.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now emphasizes newer date stamps (including an estimated last update) and a broader 2025-09 grouping, while phasing out older date entries and a generic last-update label.SummaryDifference0.2%

- Check58 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; 'Back to Top' link removed.SummaryDifference0.1%

Stay in the know with updates to MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.